KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Astrazeneca (AZN) EBT (2016 - 2025)

Historic EBT for Astrazeneca (AZN) over the last 16 years, with Q4 2025 value amounting to $2.6 billion.

  • Astrazeneca's EBT rose 5780.31% to $2.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $12.4 billion, marking a year-over-year increase of 4269.93%. This contributed to the annual value of $12.4 billion for FY2025, which is 4269.93% up from last year.
  • According to the latest figures from Q4 2025, Astrazeneca's EBT is $2.6 billion, which was up 5780.31% from $3.2 billion recorded in Q3 2025.
  • In the past 5 years, Astrazeneca's EBT registered a high of $3.4 billion during Q1 2025, and its lowest value of -$2.0 billion during Q3 2021.
  • For the 5-year period, Astrazeneca's EBT averaged around $1.5 billion, with its median value being $1.7 billion (2023).
  • Its EBT has fluctuated over the past 5 years, first plummeted by 33458.38% in 2021, then soared by 74534.41% in 2023.
  • Astrazeneca's EBT (Quarter) stood at -$636.0 million in 2021, then skyrocketed by 222.33% to $778.0 million in 2022, then increased by 15.3% to $897.0 million in 2023, then surged by 85.73% to $1.7 billion in 2024, then skyrocketed by 57.8% to $2.6 billion in 2025.
  • Its EBT was $2.6 billion in Q4 2025, compared to $3.2 billion in Q3 2025 and $3.1 billion in Q2 2025.